Pony.ai Launches Robotaxi Road Testing in Dubai; Xellar Biosystems Accelerates Global Innovative Drug R&D with AI-Powered Organ-on-a-Chip

Driven by the wave of globalization, Chinese companies are actively exploring overseas markets and seeking new growth points with innovative technologies, products, and services, showcasing their strength and风采 on the global stage. "The 'Going Overseas' Chronicle" will focus on the international business dynamics of Legend Capital's portfolio companies and present them collectively.

On September 26, Pony.ai showcased at the 2025 Dubai World Congress for Self-Driving Transport the Robotaxi vehicles set to be deployed in Dubai, along with its commercially validated L4 autonomous driving solution, which has obtained Dubai's autonomous driving road test permit. This marks a key step for the company in launching Robotaxi services in Dubai, UAE, in the Middle East.

This is the first time Pony.ai has showcased its L4 autonomous driving "Chinese solution" to the public in Dubai, attracting many visitors to experience it. Pony.ai hopes to empower regional development with autonomous driving technology, enhancing traffic safety and travel efficiency. Local government representatives and industry partners have shown strong interest in Pony.ai’s fully driverless Robotaxi technical solution and its Dubai implementation plan.

Recently, Xellar Biosystems and Ichor Life Sciences of the United States officially announced a global strategic partnership. The two parties will integrate Xellar Biosystems' leading-edge technology in FDA-standardized organ-on-a-chip solutions with Ichor Life Sciences’ full-chain CRO service capabilities to jointly advance preclinical research into a new era of "humanized precision evaluation," injecting strong momentum into the transformation of innovative achievements in the biopharmaceutical and longevity research fields.

Reportedly, the "3D-Wet-AI" closed-loop system developed by Xellar Biosystems deeply integrates high-throughput chips with AI deep learning algorithms. The automatic pathology image recognition system co-developed with Pfizer can compress hours of manual analysis into 30 seconds, and the output data fully complies with the highest international regulatory standards such as FDA and OECD. This dual advantage of "precise models + compliant data" is precisely the core requirement for the FDA’s promotion of non-animal testing alternatives.

From October 17 to October 19, the 2nd International Epilepsy Surgery Society (IESS) Conference was held in Beijing. BCIFlex was invited to exhibit and showcased two of its clinical and research products focused on neurological diseases — “Digital EEG Machine” and “Intracranial Deep Electrodes” — attracting widespread attention from top neurosurgeons, researchers, and other attendees worldwide.

At the annual meeting of the International Epilepsy Surgery Society, BCIFlex exchanged the latest advances in diagnosis and treatment technologies for neurological diseases with global experts. Motivated by this, the company will continue to advance product research and development and clinical transformation, providing new tool options for the diagnosis and treatment of complex neurological disorders, while exploring more potential pathways for the clinical application of invasive brain-computer interface technologies.

Recently, the multi-port laparoscopic surgical robot independently developed by BCIFlex® successfully completed commercial installation at Kelina Hospital in Nigeria and has been put into clinical use. This marks an important step for BCIFlex in expanding into the West African market and serves as another exemplary case of China-Africa medical cooperation and technological accessibility.

Within just two days after the installation, four prostate cancer patients successfully underwent BCIFlex robotic surgeries. The system's outstanding clinical performance has earned high recognition from the medical team. Dr. Undie, the president of Kellyna Hospital, stated: "The advanced technology platform provided by Chinese innovation offers better cost-effectiveness, and the comprehensive support services from the BCIFlex team help us serve our patients better."

On October 19, Longxin Bio announced the latest progress of its first core gene therapy product LX101 for inherited retinal dystrophy (IRD) in a pivotal Phase III clinical trial in China, during a special session at the 129th Annual Meeting of the American Academy of Ophthalmology (AAO).

Study results showed that, after 12 months of a single administration of LX101, subjects experienced statistically and clinically significant improvements in visual function, meeting the pre-specified primary endpoint. Meanwhile, LX101 demonstrated good safety and tolerability both locally and systemically. This achievement marks a groundbreaking "0 to 1" breakthrough in China’s ophthalmic gene therapy field, bringing new hope of restoring vision to patients with IRD.

Recently, the GMP-grade recombinant human interleukin-3 (IL-3) protein independently developed by Yusheng Biotechnology successfully passed the Drug Master File (DMF) registration with the U.S. Food and Drug Administration (FDA). The registration number is MF042688.

To meet the demands of the cell therapy drug development stage, Yusheng Biotech has developed GMP-grade recombinant human IL-3 and conducted comprehensive quality control tests to ensure strict standards for product purity, activity, safety, and consistency. Reportedly, this product boasts advantages such as high purity, ultra-low endotoxin levels, batch-to-batch consistency, compliance, and being animal origin-free.

Recently, Milchwald successfully completed the maritime export of Europe's largest sodium-ion energy storage cabinet. The project, located near Bremen Airport in northern Germany, has a scale reaching the megawatt-hour level. This successful delivery demonstrates the steady enhancement of Milchwald’s global service capabilities and marks significant progress in its globalization development strategy.

Note: All images in the text are provided by respective companies.